June 1, 2023
Ono Pharmaceutical said on May 31 that it has filed for an additional indication of the BRAF inhibitor Braftovi (encorafenib) and MEK inhibitor Mektovi (binimetinib) as a doublet combo therapy for radically unresectable BRAF-mutant thyroid cancer in Japan. The submission...read more